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Abstract 
This paper reviews the clinical and experimental 
findings on the effects of sodium fluoride (NaF) on 
human and animal bone. NaF has been shown to cause 
a significant increase in axial skeletal bone mass. 
However, there is concern that the new bone may not 
provide the desired increase in bone strength. Yet, NaF 
remains the most commonly used agent capable of stim-
ulating bone formation in most patients (30% non-re-
sponders).. But whether NaF reduces vertebral fracture 
rate (VFR) remains controversial. For a given treatment 
duration, the effect of F on bone quality appears to de-
pend on dose: there is a marked detrimental effect on 
bone strength at high dose but there tends to be a bene-
ficial effect at low dose. This biphasic NaF effect on 
bone strength has also been observed in fluoridated rat 
femurs. Unlike a study on young female rats which 
shows a linear dependence of cancellous bone volume 
(Cn-BV /TV) on NaF dose, a short-term study on young 
male rats, together with studies on chicks and dogs show 
biphasic NaF effects. Biphasic character is also ob-
served in the effect of NaF on the packing of canine cor-
tical bone mineral. When taken together, the animal 
models that show biphasic NaF effects seem to suggest 
that NaF at low dose improves Cn-BV/TV and bone 
strength and at high dose undermines them. These find-
ings are in agreement with the clinical observations that 
high NaF dose does not help reduce VFR but low dose 
seems to help. 
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Introduction 
In senile osteoporosis and in postmenopausal osteo-
porosis, the amount of bone resorbed is not fully com-
pensated by the amount of bone formed. This dynamic 
imbalance has to be corrected if we want to treat these 
types of osteoporosis. The corrective measures taken at 
present are mainly experimental and involve either stim-
ulating bone formation or inhibiting bone resorption. In 
normal or osteoporotic bone, the cellular processes for 
bone formation and bone resorption are coupled (Parfitt, 
1988). As a consequence, antiresorptive regimens in-
cluding estrogen, calcitonin, and bisphosphonates, will 
prevent further bone loss, but will not build up bone 
mass after one or two years. The same coupling effect 
also limits the formation-stimulating regimens from 
building up bone mass beyond the time when a new dy-
namic remodeling equilibrium is achieved (Ke et al., 
1992). However, in practice, formation-stimulating reg-
imens including sodium fluoride (NaF), parathyroid hor-
mone {PTH), and various growth factors, can build up 
bone mass more effectively, and for a longer period of 
time than antiresorptive regimens (Riggs, 1990). In 
fact, when NaF (Parfitt, 1988) or PTH (Hock et al., 
1989) or prostaglandin~ (Jee et al., 1994) is the stimu-
lating agent, there seems to be an "unbalanced coupling" 
in favour of bone formation, with some new bone for-
mation taking place on inactive bone surface without a 
preceding resorption phase (modeling in the formation 
mode). 
Oral NaF treatment, at 1 mg/kg/d, for postmeno-
pausal osteoporosis has produced mixed results. It has 
been shown to cause a significant increase in axial skele-
tal bone mass (Briancon and Meunier, 1981; Harrison et 
al., 1981; Lane et al., 1984; Eriksen et al., 1985; Riggs 
et al., 1990; Kleerekoper et al., 1991). However, there 
is concern that when NaF is given at approximately 1 
mg/kg/d, the new bone may not provide the desired in-
crease in bone strength as the new bone may be woven 
in nature and hyperosteoidosis may be present. At 1-1.4 
mg/kg/d, a long-term study has shown that hyperosteoi-
dosis after 7 years is not as severe as after 3 years 
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(Lundy et al., 1989). At lower dose, it has been report-
ed that lamellar bone without hyperosteoidosis is formed 
(Mamelle et al., 1988). Another study reports that 
defective mineralization is significantly correlated to 
high bone fluoride content (Boivin et al., 1993) and 
bone fluoride content is affected by several factors in-
cluding the dose, the bio~vailability of the compound 
used and the duration of treatment (Boivin et al., 1988). 
Also, it has been suggested that NaF increases cancel-
lous bone mineral density but decreases that of cortical 
bone, causing the non-vertebral fracture rate of patients 
to increase (Riggs et al., 19~0; Schnitzler et al., 1990b). 
On the other hand, an intermittent treatment with slow-
release NaF (50 mg/day; four 3-month cycles in 20 
months), together with continuous vitamin D and cal-
cium therapy, produces new bone with normal material 
quality (Pak et al., 1989; 1994; Zerwekh et al., 1992). 
The benefit-to-risk ratio depends on the cumulative dose. 
A treatment period of two years with low daily dose (50 
mg in enteric-coated tablets) with calcium supplement is 
considered safe (Meunier and Boivin, 1993). 
To date, NaF remains . the most commonly used 
agent capable of stimulating bone formation in most pa-
tients. However, approximately 30% of patients are 
non-responders (Hodsman and Drost, 1989). It is the 
only agent that is effective in reducing vertebral fracture 
rate (VFR) in patients with the vertebral crush fracture 
syndrome (Heaney et al., 1989). But whether NaF re-
duces vertebral fracture rate remains highly controver-
sial. Until such time that NaF can be replaced by a 
more effective drug, perhaps by antiresorptive agents 
such as bisphosphonates (Storm et al., 1990; Watts et 
al., 1990; Reid et al., 1994; Thiebaud et al., 1994), or 
by another anabolic agent such as PTH (Reeve et al., 
1980; 1991), further research on the dosage, drug prepa-
ration and duration of treatment should be continued. 
This paper attempts to review the clinical and experi-
mental fmdings on the effects of NaF on human and ani-
mal bone so as to shed light on the use of NaF to treat 
osteoporosis in humans. 
Effects of NaF on Bone 
Effects of NaF on bone quality 
Long-term NaF therapy affects bone in several 
ways. The biology and chemistry of the bone are both 
affected but to a different extent. What is observed clin-
ically is the combined result of both effects in the form 
of modified bone quantity and quality . The bone fluo-
ride content varies according to exposure time and dose. 
While the iliac biopsies of normal subjects contain 0.05 
to 0.08% by weight ofF, those of NaF treated patients 
contain 0.24 to 0.67% and those from patients with fluo-
rosis contain 0.56 to 1.33% (Boivin et al. , 1988). As 
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mentioned above, at the therapeutic dose of 1 mglkg/d, 
NaF stimulates bone formation. New bone forms on the 
surface of existing trabeculae but remodelling of the 
thickened trabeculae is lacking (Aaron et al., 1992). In 
vitro experiments also show that the fluoridated bone is 
more resistant to osteoclastic resorption (Okuda et al., 
1990) and acid dissolution (Grynpas and Cheng, 1988). 
Small-angle X-ray scattering of fluoridated bone shows 
the presence of new bone laid down on the surface of 
preexisting trabeculae (Fratzl et al., 1994). Its mineral 
structure is characterized by the presence of additional 
large crystals, presumably located outside the collagen 
fibrils. These abnormal large crystals contribute to in-
crease the bone mineral density without significantly im-
proving the bone strength (Fratzl et al., 1994). Another 
backscattered electron imaging study also shows that 
degree of mineralization increases with NaF treatment 
(Grynpas et al., 1994). Treatment duration is another 
parameter in the NaF effect on bone strength. At the 
therapeutic dose, NaF begins to show an adverse effect 
on bone strength after one year, and the effect is more 
serious after five years (Sogaard et al., 1994). 
In addition to treatment duration, the effect ofF on 
bone quality appears to depend also on dose: there is a 
marked detrimental effect on bone strength at high dose 
but there tends to be a beneficial effect at low dose 
(Lees and Hanson, 1992). This biphasic NaF effect on 
bone strength bas also been observed in fluoridated rat 
femurs (Turner et al. , 1992). Clinically , it has also 
been shown that the effect of NaF on VFR is biphasic: 
VFR decreases when the effective NaF dose is low and 
then increases when the dose is high (Riggs et al., 
1994). The biphasic character of NaF effects is ob-
served also in animal studies and will be discussed again 
in later sections. 
Effects of NaF on bone histomorphometry 
The architecture of a bone type is a major determin-
ing factor for F effect because, in addition to other path-
ophysiological factors including the rate of remodeling 
activity, the bone surface area per unit volume directly 
controls the fluoridation process. As a consequence, 
NaF is well known to affect cortical and cancellous 
bones differently (Cheng and Bader, 1990a; 1992; Riggs 
et al., 1990; Zerwekh et al., 1992). In a canine study, 
it has been shown that the cancellous F% and F /Ca in-
crease significantly with NaF dose, whereas the cortical 
F% and F/Ca do not (Cheng and Bader, 1990a; 1992). 
Effects of NaF on cancellous bone 
Extensive work has been done on the NaF effect on 
human cancellous bone. Some deal with patients suffer-
ing skeletal fluorosis (Boivin et al. , 1989). Many deal 
with the effects of therapeutic NaF dose (about 1 
mg/kg/d) . However, most of these studies employed 
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other drugs such as calcium, vitamin D and phosphorus 
in addition to NaF (Briancon and Meunier, 1981; Vigo-
rita and Suda, 1983; Eriksen et al., 1985). So, it would 
be difficult to isolate the effect of NaF alone from the 
combined results. However, there are several animal 
studies involving NaF alone, and the animals employed 
include: pigs (Mosekilde et al., 1987), sheep (Chavas-
sieux et al., 1991a; 1991b), dogs (Snow and Anderson, 
1986; Cheng and Bader, 1992), rats (Turner et al., 
1989; Cheng and Bader, 1990b; Modrowski et al., 
1992; Cheng et al., 1994), mice (Marie and Hott, 1986) 
and chicks (Lundy et al., 1986). For a complete list of 
animal models and protocols in studies on fluoride on 
bone, please see the review by Chavassieux (1990). 
Table 1 compares some static and dynamic histomorpho-
metric results for both humans and animals receiving 
non-fluorotic NaF doses. Again, one cannot compare 
human studies and animal studies directly as the former 
usually employ other drugs as well as NaF and the latter 
employ a wide range of NaF doses . In particular, rats 
are usually given NaF doses much higher than human 
therapeutic dose. Other factors that differ humans from 
animals are diet, fluoride metabolism and bone re-
modeling activity. 
Table 1 shows that in all human studies and most 
animal studies NaF significantly increases cancellous 
bone volume (Cn-BV/TV). In fact, there are a few 
human studies which did not report a significant increase 
(Schnitzler et al., l990a; Vesterby et al., 1991). How-
ever, whether or not the increase in vertebral cancellous 
bone volume will protect the patients from new spinal 
fractures is still controversial. Conflicting results have 
been reported. A Mayo Clinic report suggests that the 
increased Cn-BV /TV does not help reduce spinal frac-
ture rate (Riggs et al., 1990). But there are other re-
ports which find a reduced spinal fracture rate associated 
with the increased Cn-BV /TV (Farley et al., 1990; 
Meunier, 1990). Table 1 also shows that, in most cases, 
NaF increases the cancellous fractional osteoid volume 
(Cn-OV /BV) and osteoid surface (Cn-OS/BS). Only in 
two cases, BV /TV was significantly decreased: one in-
volved 12-month-old rats treated with high dose of NaF 
(12 mg/kg/d) (Cheng et al., 1994) and the other in-
volved young rats with an even higher dose (equivalent 
to NaF at 55 mg/kg/d) (Turner et al., 1989). These re-
sults suggest that high NaF dose is toxic to bone. Also, 
only in two studies was OS/BS reported to decrease sig-
nificantly. It should be noted that one of these two stud-
ies involved dogs on a relatively low dose (0. 7 mg/kg/d) 
for only 6 months (Snow and Anderson, 1986) and the 
other involved rats on hjgh dose (8 mg/kg/d) for 3 
months (Cheng and Bader, 1990b). In half of the cases, 
NaF also stimulates cancellous bone resorption as meas-
ured by the fractional erosion surface (ES/BS) . Based 
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on these static morphometric observations, one can 
safely say that NaF at therapeutic dose stimulates bone 
formation but also promotes bone resorption, albeit to a 
lesser extent. In most of the studies listed in Table 1, 
dynamic histomorphometric parameters were either not 
measured or non-significantly changed. From the thir-
teen entries listed in Table 1, there are only three sig-
nificant changes, an elevated mineral apposition rate in 
one case and two reduced adjusted appqsition rates in 
two other cases. Hence, no conclusions can be drawn 
with certainty from the dynamic data. 
Effects of NaF on cortical bone 
Little is known about the NaF effect on human cor-
tical bone. One study examined transiliac bone biopsies 
from 10 postmenopausal osteoporotic patients after 6 
months and again after 5 years of NaF treatment. The 
treatment had no effect on the cortical bone thickness 
but increased the porosity by 50-75% (p < 0.05). 
Also, after 5 years, the treatment increased the fraction 
of osteons undergoing remodeling, showing some degree 
of mineralization defect and lengthened remodeling 
cycles (Kragstrup et al., 1989a). In another study of 
transiliac biopsies from 29 patients suffering from skele-
tal fluorosis, both cortical thickness and porosity showed 
significant increases (38% and 120%, respectively) 
(Boivin et al., 1989). Non-vertebral fractures, including 
periarticular, femoral neck and long-bone shaft, have 
been found to be increased by NaF treatment in some 
studies (Gutteridge et al., 1984; Hedlund and Gallagher, 
1989; Riggs et al., 1990; Schnitzler et a/., 1990b). 
Non-vertebral fractures usually happen later than verte-
bral fractures (Schnitzler et al., 1990b). However, 
other studies have not confirmed their fmdings (Riggs et 
al., 1987; Mamelle et al., 1988). In any case, there is 
evidence that cortical bone rnineral density may decrease 
with NaF treatment after two years of treatment 
(Hodsman and Drost, 1989). 
Not much more is known about the effects of NaF 
on animal cortical bone. F -induced increases in femoral 
cortical bone porosity (73 %, p < 0. 05) were observed 
in pigs fed 2 mg/kg/d F for 6 months. Increased osteoid 
density and fluorochrome label density, and reduced os-
teon radius, osteon wall thickness and canal radius were 
also observed (Kragstrup et al. , 1989b). Sirnilar find-
ings were observed in the ribs of ovariectomized beagle 
dams fed 0. 7 mglkg/d NaF for 6 months, except that 
there was a signjficant decrease in cortical bone porosity 
(Snow and Anderson, 1985). 
Dose dependence of NaF effects on bone 
The therapeutic dose of NaF for continuous treat-
ment of osteoporosis is approximately 1 mg/kg/d. This 
dose is approximately 10-12 times larger than the equiv-
alent dose of drinking water containing 1 mg/1 of NaF. 
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Table 1. Effects of non-fluorotic NaF dose on static and dynamic histomorphometric results from cancellous bone. 
Briancon Vigorita Eriksen Lundy Chavassieux Chavassieux Snow and 
and Meunier and Suda et al. et al. et al. et al. Anderson 
(1981) (1983) (1985) (1989) (199la) (199lb) (1986) 
Animal Human Human Human Human Sheep Sheep Dog 
Dose mg/kg/d 1 1 1 0.6-1.4 1 3.5 0.7 
Other drugs Ca, vitD Ca, vitD Ca, P, vitD Ca 
Age 65 years 66 years 6 years 4 months 4years 
Duration 24 months 18-24 months 60 months 50 months 45 days 120 days 6 months 
(from 1st. bx) 
Target iliac iliac iliac iliac iliac iliac lumbar 
Static parameters 
(compared to 1st. bx) 
BY/TV t t t t ns ns ns 
OV/BV t t ns ns t 
' 
OS/BS t t t ns t t 
' 
ES/BS ns t t t ns t 
Tb.Th t ns t 
O.Th ns t ns t t ns 
Dynamic parameters 
MAR ns ns ns ns ns 
Aj.AR ns ns 
Notes: t = significant increase; ' = significant decrease; ns = not significant. BV = bone volume; TV = tissue 
volume; OV = osteoid volume; BS = bone surface; OS = osteoid surface; ES = eroded surface; Tb. Th = trabecular 
thickness; O.Th = osteoid thickness; MAR = mineral apposition rate; Aj.AR = adjusted apposition rate. 
Recent studies on the effect of fluoridated water on bone 
show that such low NaF dose has little or no effect on 
the prevalence of fractures (Kroger et al., 1994; Cauley 
et al. , 1995). At the therapeutic dose, there are side ef-
fects in some patients such as nausea, vomiting and os-
teoarticular pain (Briancon and Meunier, 1981; Riggs et 
al., 1982). Also, as already mentioned above, non-ver-
tebral fractures have been found to be more frequent in 
some studies. It is believed that these adverse side ef-
fects are dose related (Meunier, 1990). In fact, at high 
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dose, F is well known for its toxicity (Roholm, 1937). 
The pharmacology of high dose F-toxicity has been well 
studied (Caruso et al., 1970). Its toxicity affects many 
cellular functions in many organs including bone, 
kidney, heart, liver, gut and others. It promotes some 
but inhibits many other enzymatic processes. In addition 
to its bio-organic toxic effects, its bio-inorganic effects 
on bone and teeth mineralization and demineralization 
could become excessive and pathologic. It is therefore 
highly desirable to have NaF dose as low as possible. 
Biphasic effects of sodium fluoride on bone 
Table 1 (continued). 
Cheng Mosekilde Turner Cheng 
and Bader et al. et al. and Bader 
(1990a, 1992) (1987) (1989) (1990b) 
Dog Pig Rat Rat 
1 4.4 17 55 8 
6 years 8 months ?5 weeks 6 weeks 
9 months 6 months 21 days 3 months 
femur lumbar tibia femur 
t t t ~ t 
t t OS OS 
t OS ~ 
t ns ns 




However, the dose dependence ofF effects on bone 
has not been fully investigated. For humans, there is 
only one dose-response curve published, showing per-
cent change in bone mass per year as a function of NaF 
dose (0 to 80 mg/day) (K.leerekoper and Balena, 1991). 
At 80 mg/day, the effect of NaF begins to plateau. 
Table 1 shows that in rats high NaF dose does decrease 
Co-BY /TV (Turner et al. , 1989; Cheng et al., 1994). 
Perhaps for humans, it will take a dose > 80 mg/day to 
show adverse effects on bone mass. 
There are only six animal studies reported so far 
that studied the dose dependence of NaF. 
Biphasic NaF effect on chick bone: Chicks were 
employed in the first study. A biphasic NaF effect on 
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Modrowski Cheng · Marie 
et al. et al. and Hott 
(1992) (1994) (1986) 
Rat Rat Mouse Animal 
1 12 0.8 Dose mg/kg/d 
Other drugs 
3 months 1 year 21 days Age 
1-6 months 4 months 1 month Duration 
tibia femur cauda Target 
Static parameters 
t ~ t BY/TV 
OS OV/BV 
t OS t OS/BS 
ns ES/BS 
OS Tb.Th 
ns t O.Th 
Dynamic parameters 
ns OS MAR 
Aj.AR 
Cn-OS/BS was observed when 14-day-old chicks were 
fed NaF solutions (0-8.4 mM) for 14 days, with OS/BS 
first increasing with NaF dose peaking at 5 mM and 
then decreasing with higher NaF doses (Lundy et al. , 
1986). 
Short-tenn biphasic F effect on young male rat 
bone: In the second study, young male rats (140 g) 
were fed solutions containing 2.0 mM or 4.5 mM F ad 
libitum for 21 days. Fluoride intake was 56 or 183 
~tmol/day (equivalent to 17 or 55 mg/kg/d NaF). Tibial 
metaphyseal Cn-BV /TV was significantly increased at 
2.0 mM F, but was significantly decreased at 4.5 mM. 
With these two doses and the short treatment duration, 
osteoblastic and osteoclastic surfaces were not signifi-
cantly affected (Turner et al., 1989). 
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Figures 1 and 2. Analysis of canine proximal femoral cancellous bone volume (Fig. 1 at left) and cancellous mineral 
apposition rate (Fig. 2 at right) according to bone fluoride content. 
Long-tenn linear NaF effect on young female rat 
bone: In the third study, young female Wistar rats were 
fed NaF solutions (0-6 mM) with different concentra-
tions ad libitum for three months. The equivalent NaF 
dose employed ranged from 0 to 25 mg/kg/d. Although 
femoral metaphyseal Cn-BV /TV was shown to increase 
with dose, both Cn-OS/BS and Cn-ES/BS were shown 
to decrease with dose suggesting NaF toxicity , at least 
at the highest dose. Despite reduced bone formation 
activity , a positive bone balance was achieved at all 
doses and was attributed to more severely reduced bone 
resorption activity (Cheng and Bader, 1990b). How-
ever, when aged OVX rats (12 months old) were treated 
with 10-12 mg/kg/d of NaF for four months, not only 
was Cn-BV /TV not increased, but actually decreased 
when compared to untreated OVX rats. This adverse 
NaF effect on rat bone is probably age-related as this 
dose range is slightly toxic only to old rats , as evidenced 
by loss of body weight, but not to young rats (Cheng et 
al., 1994). In the young rats, NaF builds up bone by 
inhibiting bone resorption more than bone formation 
(Cheng and Bader, 1990b); but in the old rats, NaF 
loses bone by promoting bone resorption more than bone 
formation (Cheng et al., 1994). 
Possible biphasic NaF effect on adult rat bone: 
In the fourth study, 3-month old female rats were treated 
with drinking water containing either 5. 3 or 7. 9 mM 
NaF for 90 days. Although the lumbar vertebral body 
ash weight was significantly increased by each dose, the 
vertebral trabecular bone volume was increased signifi-
cantly only by the lower dose, suggesting possibly NaF 
had a biphasic effect in this model. Results from bio-
mechanical testing on the vertebral bodies showed that 
NaF at these doses did not affect bone strength signifi-
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cantly but decreased the bone quality significantly 
(Sogaard et al., 1995). 
Biphasic NaF effect on canine bone: We studied 
the dose dependence of NaF effects on bone in dogs. 
Ovariectomized beagle dams (6-7 year old) were fed 
NaF powders in pellets at four levels (0, 1, 3, 5 
mg/kg/d) for nine months. Static and dynamic histo-
morphometric results as observed in ribs and femurs 
showed that NaF had a biphasic effect on most bone pa-
rameters (Cheng and Bader, 1990a; 1992). Unfortunate-
ly, there were only two dogs at each NaF level. _In or-
der to have a meaningful analysis of the data, we have 
reanalyzed the data as functions of bone F content. Fig-
ure 1 shows that the effect of NaF on proximal femoral 
metaphyseal Cn-BV /TV is biphasic (R = 0. 764) with a 
maximum at 0.45% bone F content, which is equivalent 
to a NaF dose of approximately 2 mg/kg/d. Femoral 
cancellous mineral apposition rate (Cn-MAR) behaves 
similarly (Figure 2). However, Cn-OV/BV or Cn-
OS/BS, which was significantly elevated by NaF at all 
doses, did not show a biphasic pattern. The significant 
hyperosteoidosis may be indicative of impaired bone 
mineralization. 
Lack of favorable NaF effects on ewe bone: In a 
short-term (45 days) study on 6-year-old ewes, NaF at 
1 or 5 mg/kg/d significantly decreased serum calcium 
and phosphorus, and non-significantly decreased iliac 
cancellous bone area. Both osteoid surface and eroded 
surface were increased significantly. Dynamic parame-
ters showed that single and double labeled surfaces and 
adjusted apposition rate were non-significantly decreased 
while the mineralization Jag time was significantly 
increased (Chavassieux et al. , 1991a). 
Biphasic effects of sodium fluoride on bone 
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Figure 3. Effect of NaF on canine femoral cortical bone mineralization profile as determined by density fractionation. 
Dogs were treated with NaF for nine months. Baseline animals were killed at the beginning of the experiment. 
Effects of NaF on bone mineral 
Normal bone mineral is poorly crystalline hydroxy-
apatite [HAP, Ca10(P04)6(0HhJ, with dimensions rang-
ing from 10 to 30 nm in length and 5 to 10 nm in thick-
ness. Besides being very small and strained, the crys-
tallites contain many impurities such as C03, Mg, Na, 
etc., some of which have been reported to vary with 
fluoride content. Fluoride substitutes for the hydroxyl 
ion in apatite to form the thermodynamically more sta-
ble, less soluble, albeit still poorly crystalline, fluorhy-
droxyapatite [FHAP, CaJO(P04)6Fx(OH)z_xJ (Eanes and 
Reddi 1979; Neuman and Neuman 1958). F ions do 
not seem to diffuse into preformed HAP crystallites 
which are not near the bone surface, but are incorpo-
rated into FHAP crystallites during new bone minerali-
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zation (Grynpas, 1990). FHAP and HAP crystallites 
have very similar dimensions, except that FHAP may 
have slightly larger cross-sectional areas (Posner et al., 
1963; Grynpas et al., 1986). No change inCa, P, or 
Ca/P molar ratio have been reported for fluoridated bone 
minerals, but significant changes in Mg, C03 , Na, cit-
rate and ash weight have been reported (Zipkin et al. , 
1960). Since bone quality and bone strength depend on 
the bone micro-architecture at the bone mineral level, 
the effects of fluoride on the physicochemical properties 
of FHAP crystallites are as important as the effects on 
bone biology. Firstly, the manner in which the minerals 
are formed in the bone matrix , e.g. , packing density, 
will affect the bone strength. Secondly, the manner in 
which F is incorporated into bone mineral crystallites 
may depend on the bone microarchitecture. 
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The following two sections seek to relate changes in 
fluoridated bone mineral properties to the biphasic ef-
fects of NaF on bone as well as to the differential NaF 
effects on cortical and cancellous bones. 
Effects of NaF on bone mineral packing density and 
surface area 
Although FHAP and HAP crystallites have similar 
dimensions, bone mineral crystallites are packed closer 
together in fluoridated rat bone. When fmely ground rat 
bone powders were fractionated according to their densi-
ties, the percent by weight of powders having a density 
greater than 2.1 g/ml was always significantly higher in 
fluoridated bone than in control. The F content was also 
highest in the same density fraction, indicating that fluo-
ride increased bone mineral packing density (Grynpas et 
al., 1986). This finding is supported by the observation 
that fluoride reduces bone mineral aggregate surface 
area. When rat bones were deproteinized and their bone 
mineral aggregate surface areas were studied by nitrogen 
adsorptiometry, fluoridated bone showed significantly 
lower aggregate surface area per gram of bone than con-
trol (Cheng and Bader, 1990b). However, this finding 
in rats has not been confirmed in dogs. When canine 
femoral cortical bone powders were analyzed by density 
fractionation, the results showed that there was a hi-
phasic NaF effect on bone mineral packing. As can be 
seen in Figure 3, which shows the mineralization pro-
files of untreated and treated canine cortical bones (at 
four dose levels), in the density fraction between 2.0 and 
2.1 g/ml, there is a peak at the dose of 1 mg/kg/d while 
in the density fraction between 2.1 and 2.2 g/rnl, there 
is a trough at the same dose. These two density frac-
tions are the more important and sensitive fractions of 
the four shown in the figure. Together, they show that 
at low dose, NaF promotes hypomineralization (favoring 
lower density fractions) and at high dose, it promotes 
hypermineralization (favoring higher density fractions). 
Since increased mineral packing density could lead to a 
more brittle bone, especially for cortical bone, this 
adverse NaF effect at high dose could be considered 
negative for bone quality. 
Fluoride-lattice interactions in bone mineral 
Another interesting physical phenomenon of fluori-
dated bone is the fluoride-lattice interactions in bone 
mineral crystallites. This can be measured by 19F 
nuclear magnetic resonance (NMR) in terms of the spin-
lattice relaxation time (T 1). As with neutron activation 
analysis, 19F NMR can be used to measure the bone F 
content non-invasively (Code et al. , 1990b). We have 
studied 19F nuclear spin-lattice relaxation rates in corti-
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cal and cancellous bones from rats and dogs and have 
found that 19F NMR results are species independent, but 
are dependent on the magnetic field strength and the 
bone fluoride concentration. The results suggest that 
there are at least two chemically inequivalent F incorpo-
ration sites in bone tissue, possibly a surface site and a 
bulk site (Code et al., 1990a). In agreement with neu-
tron activation analysis results , 19F NMR shows that 
cortical bone always takes up significantly less F than 
cancellous bone. More important, we have observed 
that for a given bone F concentration, cortical and can-
cellous bones do not have the same T 1 values such that 
cortical T 1 is significantly shorter than cancellous T 1, 
suggesting a stronger fluoride-lattice interaction in corti-
cal bone mineral crystallites. For each bone type, l!T1 
is linearly dependent on bone F content, i.e. , the higher 
the bone F content, the shorter the T 1, but the regression 
coefficients are different for cortical and cancellous 
bones. This also indicates that the local environments of 
fluoride in cortical bone and in cancellous bone are not 
the same. The longer T 1 in cancellous bone is not relat-
ed to the higher organic matrix content. It is probably 
related to the fact that cancellous bone has a higher per-
centage of F incorporating surface sites than cortical 
bone (Code et al . , 1992). This hypothesis can also ex-
plain the shorter T 1 values for more fluoridated bones as 
bone F depresses the bone mineral aggregate surface 
area (Cheng and Bader, 1990b). 
Conclusions 
Unlike the 3-month study on young female rats 
which shows a linear dependence of Cn-BV /TV on NaF 
dose, the 21-day study on young male rats and the stud-
ies on chicks and dogs show biphasic NaF effects on 
Cn-OS/BS in chicks and on Cn-BV /TV in dogs and in 
young male rats. Biphasic character is also observed in 
the effect of NaF on the packing of canine cortical bone 
mineral. When taken together, the animal models that 
show biphasic NaF effects seem to suggest that NaF at 
low dose improves Cn-BV /TV and at high dose under-
mines it. The results on bone strength and bone quality 
are more difficult to assess. At high NaF dose, bone 
strength suffers. But no clear verdict can be arrived at 
present for the effect on bone strength when low NaF 
dose is employed. In humans, high NaF dose does not 
help reduce VFR but low dose seems to help. Low NaF 
dose (50 mg/d) given in enteric-coated tablets with cal-
cium supplement for 2 years is considered safe (Meunier 
and Boivin, 1993). But, even at therapeutic dose, long-
term (5 years) NaF treatment may be detrimental to 
bone strength and quality , as test results on trabecular 
bone from iliac biopsies have shown (Sogaard et al. , 
1994). 
Biphasic effects of sodium fluoride on bone 
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Discussion with Reviewers 
L. Mosekilde: How do the authors defme bone 
strength? The authors have referred to several papers 
where indirect measurement of bone strength has been 
performed (e.g., "sonic velocity:); on the other hand, 
several papers where direct measurements ofbiomechan-
ical strength of fluoride treated bone have been made 
have been omitted or mentioned only very superficially 
by the authors. 
Authors: Ultimately , bone strength is measured by 
bimechanical testing. Indirect measurements should be 
of value too, and hence should not be overlooked. 
L. Mosekilde: Do the authors consider that high-dose 
or long-term treatment has a negative effect on "bone 
biology" , and on "bone chemistry"? 
Authors: High-dose is defmitely the ultimate culprit. 
In fluorosis, both bone biology and bone chemistry are 
abnormal. As for therapeutic doses, long-term treatment 
also has adverse effects on bone strength which we 
believe are caused by a change in bone "physical 
chemistry" . 
L. Mosekilde: What is the relationship in time between 
effect on "bone biology" and "bone biochemistry"? 
Authors: If NaF dose is high enough to affect bone cell 
biology, it will not take long to affect bone biochemis-
try, e.g., over production of collagen matrix. If the 
dose is too low to affect bone cell biology significantly, 
only the cumulative F effects on physical chemistry 
(crystallography) and material science of bone mineral 
will be observed after prolonged exposure. 
W.S.S. Jee: Does NaF have any anabolic effects on 
periosteal and endocortical surfaces like PTH and PG~? 
Authors: To our knowledge, no rat data on cortical 
bone is available. NaF has anabolic effects on endocor-
tical surfaces. We are not sure whether it is also true 
for periosteal surface. 
P. Chavassieux: For a better understanding, it is essen-
tial to distinguish the effects of fluoride on bone cells 
and on bone mineral, both contributing to the quality of 
bone. Concerning the first one, it is now well estab-
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lished that fluoride induces an osteoblastic proliferation 
probably through the osteoblast precursors. Besides this 
stimulatory effect, fluoride may decrease the osteoblast 
activity at the individual cell level. The amplitude of 
these effects depends on the total amount of fluoride in-
gested and may explain the different results in the litera-
ture. It will be important to understand the effects of 
fluoride in bone cells to completely understand fluoride 
effects on bone. 
Authors: The effects of fluoride depends on two things: 
dose and treatment duration. For a given dose, the 
treatment duration counts; and for a given duration, the 
dose counts. The effect of fluoride on bone cells is be-
yond the scope of this review. We do not consider our-
selves experienced enough in this area to draw conclu-
sions from the conflicting results published. 
P. Chavassieux: Concerning the effects of fluoride on 
bone mineral, all data reported in this paper concern 
only animal studies. Is there any human study after 
fluoride treatment or in cases of fluorosis? 
Authors: Only some early human studies mentioned ef-
fects of fluoride on bone mineral, but mostly on their 
chemical composition . 
